Alps Advisors Inc Avadel Pharmaceuticals PLC Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 04, 2019	SELL	$1.74 - $4.66 $123,423 - $330,547	-70,933 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$4.08 - $7.14 $52,068 - $91,120	12,762 Added 21.94%	70,933 $311,000
Q2 2018 Aug 02, 2018	BUY	$5.89 - $7.78 $81,005 - $106,998	13,753 Added 30.96%	58,171 $357,000
Q2 2018 Jul 25, 2018	SELL	$5.89 - $7.78 $55,024 - $72,680	-9,342 Reduced 17.38%	44,418 $364,000
Q1 2018 May 01, 2018	BUY	$6.76 - $11.7 $63,151 - $109,301	9,342 Added 21.03%	53,760 $392,000
Q4 2017 Feb 05, 2018	BUY	$8.03 - $11.25 $39,684 - $55,597	4,942 Added 12.52%	44,418 $364,000
Q3 2017 Nov 03, 2017	BUY	$8.35 - $10.5 $329,624 - $414,498	39,476	39,476 $414,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $477M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.